"The FDA approval of Avapro for this new indication marks an important advance in the treatment of patients with high blood pressure, type 2 diabetes and kidney disease," said Edmund Lewis, MD, professor of nephrology and director of the Section of Nephrology at Rush Medical College in Chicago, Illinois. "As a result of this decision physicians now have a new option to help manage this serious condition that affects millions of Americans."
The FDA approval is based on results from the Irbesartan Diabetic Nephropathy Trial (IDNT) which studied patients with high blood pressure, type 2 diabetes and evidence of kidney disease. Data from the IDNT trial, published in The New England Journal of Medicine, demonstrated that when these patients were treated with Avapro there was a reduction in the risk of their kidney disease progressing, or death, that was 20 percent lower than the placebo (control) group (p=0.02) and 23 percent lower than the group treated with amlodipine, a calcium-channel blocker (p=0.006).
"As a result of the IDNT trial, we have more data supporting the importance of early treatment of diabetic kidney disease," added Dr. Lewis. "The approval of Avapro means that we now have a new treatment option that can be used to help slow the progression of kidney disease, and delay or avoid the need for dialysis or a kidney transplant."
Taking into account the results of clinical trials such as IDNT, the American Diabetes Association (ADA) issued guidelines that officially recommend angiotensin II receptor blockers, such as Avapro, as the initial agent of choice in the treatment of high blood pressure patients with type 2 diabetes and evidence of kidney disease.
No adverse events were reported among Avapro-treated patients in IDNT that were not previously reported in Avapro high blood pressure trials. Patients in this study, however, reported orthostatic symptoms (e.g., dizziness and low blood pressure) and increases in serum potassium more often in the Avapro-treated group than the control group. In addition, as soon as pregnancy is detected, patients should discontinue Avapro therapy (see boxed WARNING regarding Use in Pregnancy in full prescribing information).
In earlier clinical hypertension trials, there were no significant differences in adverse events between Avapro and placebo. Adverse events that occurred in at least 1 percent of patients treated with Avapro and at a higher rate versus placebo included diarrhea, dyspepsia/heartburn and fatigue.
Available for five years, irbesartan is marketed worldwide by Bristol-Myers Squibb and Sanofi-Synthelabo under the brand names of Avapro®, Aprovel
Visit Bristol-Myers Squibb on the World Wide Web at www.bms.com
Visit Sanofi-Synthelabo on the World Wide Web at www.sanofi-synthelabo.com
ADDITIONAL CONTACT INFORMATION:
Bristol-Myers Squibb
Caroline Almeida
Tel: 609-252-4609
Sanofi-Synthelabo
Jean-Marc Podvin
Tel: 33-1-53-77-42-23
Leslie Hare
Tel: 212-551-4007